文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

氯法齐明治疗隐孢子虫病的随机对照试验方案

Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-08-23

CRYPTOFAZ 是一项随机、双盲、安慰剂对照试验,计划招募 66 名 HIV 感染合并隐孢子虫慢性腹泻患者,口服氯法齐明或安慰剂 5 天,评估安全性与耐受性,并以粪便隐孢子虫排出量减少及血浆药代动力学为主要终点。

要点

  • 氯法齐明在体外和小鼠感染中显示抗隐孢子虫活性,HIV 感染者体内疗效与药代动力学未知。
  • 主要终点为 5 天内粪便隐孢子虫排出量较安慰剂的减少,以及末次给药后血浆药代动力学参数。
  • 研究另设开放标签部分,比较 HIV 感染者伴或不伴隐孢子虫腹泻时氯法齐明的药代动力学。

核心结论

  • 该方案旨在评估氯法齐明治疗 HIV 感染者隐孢子虫腹泻的安全性、耐受性、药代动力学和抑制隐孢子虫的活性。

研究设计与样本

  • CRYPTOFAZ 包括随机、双盲、安慰剂对照试验,以及一项开放标签药代动力学比较。
  • 计划招募 66 名 HIV 感染合并隐孢子虫慢性腹泻的受试者。
  • 受试者住院期间接受氯法齐明或安慰剂 5 天,出院后随访。
  • 隐孢子虫诊断以定量 PCR 为确证试验,粪便 ELISA 用于定量排出量。
  • 药代动力学在血浆和粪便样本中研究。

关键数值与推荐

  • 主要终点包括 5 天内粪便隐孢子虫排出数量较安慰剂组的减少。
  • 主要终点还包括末次给药后血浆氯法齐明药代动力学,评估曲线下面积、血浆峰浓度和半衰期(T½)。

临床怎么用

  • 研究为马拉维及撒哈拉以南非洲多数地区缺乏确定性治疗的 HIV 合并隐孢子虫腹泻患者探索可能的治疗选择。
  • 若证实有效且安全,将为后续在 6–18 月龄儿童中研究氯法齐明奠定基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cryptosporidium infection and diarrhea (cryptosporidiosis) is a life-threatening infection in persons with HIV and also in children of 6-18 months of age in the developing world. To date, only nitazoxanide is licensed for treatment of cryptosporidiosis, and only in persons after the first year of life and with healthy immune systems. Clofazimine (CFZ: Lamprene®), an established drug that has been used for leprosy for more than 50 years, recently has been described as effective against Cryptosporidium in vitro and in mouse infections. The efficacy and pharmacokinetics of CFZ in vivo, in HIV-infected patients with cryptosporidial diarrhea are not known. METHODS: CRYPTOFAZ includes a randomized, double-blind, placebo-controlled study of the safety, tolerability and Cryptosporidium inhibitory activity of orally administered CFZ in subjects with HIV infection and chronic diarrhea with Cryptosporidium. An additional open label aspect of the study will compare the pharmacokinetics (PK) of orally administered CFZ in HIV-infected individuals with and without Cryptosporidium-associated diarrhea. The study will recruit a total of 66 subjects. Study participants will be given either CFZ or a placebo for 5 days while in hospital and will be followed up after discharge. Cryptosporidium will be diagnosed by quantitative PCR as the definitive test and by stool ELISA, which will also be used to quantify the shedding of Cryptosporidium in stool. PK will be studied on plasma and stool samples. Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose. DISCUSSION: This study provides an opportunity to explore a possible treatment option for HIV-infected patients with cryptosporidial diarrhea, who, as of now in Malawi and most of sub-Saharan Africa, do not have a definitive treatment apart from supportive care. The strength of this study lies in it being a randomized, double-blind, placebo-controlled trial. If shown to be effective and safe, the findings will also lay a foundation for a future study of the use of CFZ in children 6-18 months of age. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03341767 . Registered on 14 November 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nachipo P, Hermann D, Quinnan G, et al. Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial. Trials. 2018. PMID: 30139372. doi:10.1186/s13063-018-2846-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。